EP1158909A1 - Methodes et appareil destines a la therapie transcutanee par champs uniforme d'ultrasons - Google Patents

Methodes et appareil destines a la therapie transcutanee par champs uniforme d'ultrasons

Info

Publication number
EP1158909A1
EP1158909A1 EP00914604A EP00914604A EP1158909A1 EP 1158909 A1 EP1158909 A1 EP 1158909A1 EP 00914604 A EP00914604 A EP 00914604A EP 00914604 A EP00914604 A EP 00914604A EP 1158909 A1 EP1158909 A1 EP 1158909A1
Authority
EP
European Patent Office
Prior art keywords
ultrasound
ultrasound energy
target region
field
transducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00914604A
Other languages
German (de)
English (en)
Other versions
EP1158909A4 (fr
Inventor
Axel F. Brisken
Robert Zuk
John R. Mckenzie
Mark W. Cowan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasonics Inc
Original Assignee
Pharmasonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasonics Inc filed Critical Pharmasonics Inc
Publication of EP1158909A1 publication Critical patent/EP1158909A1/fr
Publication of EP1158909A4 publication Critical patent/EP1158909A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis

Definitions

  • the present invention relates to ultrasound systems for delivering therapeutic ultrasound energy to a target region of a patient's body.
  • a current standard technique for the delivery of drugs or other substances into the human body is needle injection, in particular, intramuscular injection (IM).
  • IM intramuscular injection
  • a bolus containing the substance is typically injected into muscle where it diffuses through the interstitial fluid or pools between muscle layers and thence diffuses through the same or more distant interstitial fluid. This diffusion might spread over a length of five or more centimeters parallel to the muscle fibers and over a width of perhaps one or two centimeters normal to the fibers.
  • the vascular system of the body takes over and flushes the substance out of the interstitial fluid and into the capillaries. From there, the cardiovascular system widely distributes the substance into the rest of the patient's body.
  • Newly developed drugs often have application only to specific organs or sections of organs. As such, systemic distribution of the drug throughout the remainder of the body can: (1) dilute very expensive drugs, weakening their effects, (2) generate an effect systemically instead of locally, and (3) widely distribute a drug which may be toxic to other organs in the body. Furthermore, some of the newly developed drugs include DNA in various forms, such DNA being degraded very rapidly by natural mechanisms in the body if delivered systemically, thus preventing a full dose from reaching the designated organ.
  • the enhancement mechanism it would be desirable for the enhancement mechanism to be mechanical in origin, as compared to thermal in origin. Mechanical methods may function to temporally permeabilize cellular membranes as compared to thermal mechanisms which may give rise to tissue inflammation.
  • VEGF vascular endothelial growth factor
  • Ultrasonic systems which might be ineffectively used for enhanced transfection of DNA or for the cellular uptake of other drugs by various biological cells do exist.
  • these systems produce very narrow ultrasound beams due to operation in the focal zone or far field (Fraunhofer zone) or they produce broad irregular fields due to operation in the near field (Fresnel zone).
  • the narrow beams cannot deliver a satisfactory dose of ultrasound to the volume of tissue in a time frame short compared to the natural biological destruction of the DNA.
  • the irregular fields are characterized by large differences in acoustic intensity both in the lateral direction (parallel to the transducer surface) and in the axial direction (normal to the transducer surface), such differences leading to unpredictable amounts of ultrasound dose.
  • Systems which operate in the focal zone and far field include medical diagnostic ultrasound imaging and Doppler systems. These feature very tight acoustic scanning beams for the purpose of achieving the highest possible lateral resolution. Furthermore, ultrasound tissue exposure in scanning beams is held to the frame rate of the system display, typically 30 Hz. Maximum signal strengths are limited by industry and FDA guidance protocols. These systems furthermore operate at higher frequencies, in the range where longer bursts of ultrasound or continuous ultrasound exposure would create a heating effect due to absorption of the ultrasound energy in the tissues. These systems would be incapable of delivering the mechanical ultrasound effects to achieve acceptable therapeutic effects.
  • Additional systems which operate with highly focused beams include low frequency lithotripters and high frequency thermal ablation systems.
  • Lithotripters feature short bursts of high intensity ultrasound with a very low burst repetition rate. They cannot provide broad tissue coverage with a high duty cycle.
  • Ablation systems typically identified as high intensity focused ultrasound (HIFU) systems, function to create thermal lesions in living tissue. While their acoustic beams might be swept through tissue for wide area coverage, their high frequency operation fails to produce mechanical effects in tissue.
  • HIFU high intensity focused ultrasound
  • the present invention provides systems, methods and kits for delivering a uniform field of ultrasound energy over a wide target region of a patient's body.
  • the present invention offers the advantages of enhancing cellular absorption and or transfection of therapeutic substances delivered by injection into a patient's body.
  • the present invention is also useful for the treatment of vascular structures at risk from intimal hyperplasia.
  • the present invention provides a variety of wide beam ultrasound delivery systems which have the advantage of delivering therapeutic ultrasound energy over a large tissue volume such that, in preferred aspects, ultrasound energy can be uniformly distributed over the region in which a therapeutic substance has been injected intramuscularly, in a short time frame as compared to the lifetime of the substance at the site of interest.
  • An advantage of the present invention is that by applying a uniform field of ultrasound energy over a large tissue volume, cellular uptake of injected substances such as therapeutic DNA can be substantially enhanced over the entire region in which the injected DNA spreads without inflicting tissue damage or degrading the injectate.
  • Another advantage of the present invention is that by applying a uniform field of ultrasound energy over a long length of vascular structure, a healing response might be invoked to blunt excessive growth of intimal hyperplasia without adjacent tissue damage.
  • An advantage of the present invention is that it provides systems for both delivering wide ultrasound beams and for scanning ultrasound beams. As such, the present invention is particularly well adapted to operate under both conditions in which time constraints are present and conditions under which time constraints are not present, as follows.
  • therapeutic applications which operate with pulse wave (PW) exposure by ultrasound may also require devices which have fields of view larger than the insonication area of interest if the ultrasound beam cannot be shifted away from a first sonication site during the OFF time to a second (or third, or fourth,...) sonication site for the ON time of that second (or third, or fourth,...) site.
  • duty cycle is defined as the ratio of the ON time divided by the ON and OFF time
  • the ultrasound beam may be swept across a multitude of alternative sites, the net effect being a similar amount of ultrasound exposure (uniform exposure) to all points within the subject area of interest.
  • the present wide beam ultrasound delivery system comprises a housing having an opening at its distal end with an ultrasound transducer suspended within the housing.
  • the ultrasound transducer is positioned in contact with an acoustic couplant material which substantially fills the housing.
  • the acoustic couplant material is a fluid such as water, water with additives such as wetting agents and or anti biological agents (to prevent build up of bacteria or fungus), or oils.
  • a flexible skin-contact window which may be made from any of several variations of silicone rubber, polyethylene, polypropylene, nylons, urethanes and the like, is disposed across the opening at the distal end of the housing.
  • the skin-contact window is preferably positioned adjacent to the patient's skin with possibly an ultrasonic coupling gel between the window and skin such that therapeutic ultrasound energy can be conducted from the ultrasound transducer along through the fluid-filled housing and then through the skin-contact window and into the patient.
  • the housing of the ultrasound delivery system is designed to assure good coupling of ultrasonic energy to the external configuration of the patient. Additionally the housing preferably contains adequate ultrasonic absorbing materials such that ultrasonic energy does not propagate to the external surface of the housing thus sonicating the operator of the equipment.
  • the housing preferably is designed such that it does not interfere with the ultrasonic beam in the form of unintended ultrasonic beam stops.
  • the piezoelectric element of the ultrasound transducer is generally planar and may either be rectangular, circular, or annular in shape.
  • the transducer may comprise a plurality of annular-shaped piezoelectric elements disposed concentrically, one within another.
  • the transducer may comprise piezoelectric elements which are generally cylindrical in shape.
  • the transducer may comprise single or multiple element three dimensional piezoelectric shapes.
  • the transducer may comprise a two-dimensional array of individual flat-plate piezoelectric elements.
  • the transducer elements of the present invention preferably have a large surface area ranging, in preferred aspects, from typically 0.5 cm 2 to 1000 cm 2 .
  • the shape of the piezoelectric element of the transducer in association with any and all focussing elements will effect the shape of the ultrasonic footprint in tissue, defined as the area of therapeutically effective ultrasound.
  • Some applications of the present systems may preferably use circular footprints while others may preferably use rectangular shapes.
  • an unfocussed rectangular transducer might produce a rectangular footprint with the long axis of the transducer being orthogonal to the long axis of the footprint.
  • the present invention also comprises various systems for directing the ultrasound energy through the fluid filled housing to targeted depths in the patient's body. Such systems may optionally comprise curving the piezoelectric ceramic to shape the beam width.
  • lens structures may be attached to the front emission surface of the piezoelectric ceramic to effect the same.
  • reflective surfaces may be installed in the housing so as to achieve the same.
  • refractive acoustic lenses may be placed in the acoustic beam in the fluid couplant medium to shape the beam width.
  • the back surface of the piezoelectric ceramic is covered with air to assure the emission of all acoustic energy out the front surface of the same. Consequently thermal dissipation corresponding energy backward radiated in the device will be substantially reduced and maximal efficiency achieved.
  • the back surface of the ceramic may instead be covered with low impedance lightly attenuating materials to provide some level of structural strength to the device.
  • the edges of the piezoelectric ceramic are mounted within the housing so as to minimize acoustic coupling to the housing.
  • first and second mounting systems are provided for connecting the transducer to the interior of the housing such that the transducer can be articulated for controllable back-and-forth scanning movement of a beam of ultrasound energy.
  • a narrower beam of ultrasound energy can be raster scanned across the desired volume of tissue in the patient and over time achieve uniform illumination of subject tissues.
  • the present invention is particularly well suited for (although not constrained to) use in conjunction with intramuscular injections of therapeutic substances such as DNA.
  • the present wide aperture ultrasound delivery system can be used either before, concurrently with, immediately after, or substantially after the injection of a therapeutic substance into the patient.
  • application of ultrasound "substantially after" injection comprises application of ultrasound in the period of time before which the injected DNA has been substantially degraded. Typically, such a time period will be on the order of 15 to 60 mins., but is not so limited and may vary from one application to another.
  • the present invention is ideally suited for enhancing cellular absorption of a drug or any other substance into a local target region of a patient's body, thereby avoiding the undesirable effects of the substance being widely dispersed throughout the patient's body by the patient's cardiovascular system.
  • specific applications of the present invention include the application of sonicated VEGF therapy for the treatment of ischemic tissues as described above.
  • Further applications include the treatment of patients suffering from diseases as a result of specific protein deficiencies. Specifically, such patients may be helped by the injection of specific DNA plasmids to stimulate cells to secrete these proteins, such as EPO for patients with impaired production of red blood cells, Factor VIII or Factor IX for hemophiliac patients, or angiostatin or endostatin for cancer patients.
  • EPO DNA plasmids to stimulate cells to secrete these proteins
  • EPO EPO
  • Factor VIII or Factor IX for hemophiliac patients
  • angiostatin or endostatin for cancer patients.
  • the present system's advantageous applications of a uniform wide beam ultrasound exposure are not limited to those in conjunction with substance injection.
  • the present invention is also particularly well suited for use in the prevention of intimal hyperplasia in conjunction either before, concurrently with, immediately after, or substantially after vascular intervention or surgery.
  • a further advantageous application of the present invention is its ability to distribute a uniform wide beam of ultrasound for a mechanical (non thermal) effect to evoke a vascular healing response along an extended portion of artery or vein.
  • vascular tissues at risk of intimal hyperplasia such as coronary or peripheral arteries following vascular intervention or veins and arteries following graft insertion or the creation of a fistula
  • vascular intervention with devices such as angioplasty balloons, arthrectomy catheters, or stents
  • the extent of vascular injury might range from a few millimeters in length to several centimeters or more in length.
  • the present invention also encompasses wide beam aperture systems for delivering a wide field of uniform ultrasound to a region of tissue to inhibit intimal hyperplasia in the vascular system.
  • patients receive a wide field of uniform ultrasound exposure from external sources either during the initial vascular intervention or some period thereafter.
  • Such transcutaneous uniform acoustic intensity is preferably of a sufficient power so as to excite the healing response yet is not excessively strong to evoke an inflammatory response or to lyse blood or tissue cells.
  • the present invention is not limited as to the nature of the cells which compose the target site.
  • Such cells may be muscle or organ cells receiving transcutaneous, intraoperative, or percutaneous injection.
  • Such cells may include vascular cells.
  • Fig. 1 illustrates an ultrasound system enhancing transfection of injected substance in skeletal muscle.
  • Fig. 2 illustrates an ultrasound system treating vascular sections following surgery.
  • Fig. 3 illustrates a preferred lateral beam profile superimposed upon a target region in a patient's body.
  • Fig. 4 illustrates a preferred axial beam profile superimposed upon a target region in a patient's body.
  • Fig. 5 illustrates conventional medical diagnostic ultrasound imaging of the human body.
  • Fig. 6A illustrates a lateral in-plane beam profile from a medical diagnostic imaging system.
  • Fig. 6B illustrates a lateral cross-plane beam profile from a medical diagnostic imaging system.
  • Fig. 7 illustrates axial beam profiles from a medical diagnostic imaging system.
  • Fig. 8 illustrates the application of therapeutic ultrasound for "deep heat” treatment of human muscles.
  • Fig. 9 illustrates a modeled lateral beam profile from a typical physical therapy ultrasound system.
  • Fig. 10 illustrates a modeled axial beam profile from a typical physical therapy ultrasound system.
  • Fig. 11 is a sectional side elevation view of a first embodiment of the present wide aperture beam delivery system.
  • Fig. 12A illustrates a modeled lateral beam profile of the transducer of Fig. 11.
  • Fig. 12B illustrates another modeled lateral beam profile of the transducer of Fig. 11.
  • Fig. 13 illustrates a modeled axial beam profile of the transducer of Fig.
  • Fig. 14 depicts a simplified block diagram of an electronic system to drive the transducer of Fig. 11.
  • Fig. 15 is a sectional side elevation view of a second embodiment of the present wide aperture beam delivery system, having a curved ultrasound transducer.
  • Fig. 16 is a sectional side elevation view of a third embodiment of the present wide aperture beam delivery system, having an acoustically-refractive material mounted to the transducer.
  • Fig. 17 is a front view of the acoustic aperture of an annular array transducer.
  • Fig. 18 depicts a simplified block diagram of an electronic system to drive the transducer of Fig. 17.
  • Fig. 19 illustrates a modeled lateral beam profile of the transducer of Fig.
  • Fig. 20 illustrates the modeled axial beam profile of the transducer of Fig. 17.
  • Fig. 21A illustrates a modeled proximal lateral beam profile of the transducer of Fig. 17.
  • Fig. 2 IB illustrates a distal lateral beam profile of the transducer of Fig. 17.
  • Fig. 22 is a sectional side elevation view of a fourth embodiment of the present wide aperture beam delivery system, having a cylindrical-shaped transducer.
  • Fig. 23 is a sectional side elevation view of a fifth embodiment of the present wide aperture beam delivery system, having an annular-shaped transducer.
  • Fig. 24 is a sectional side elevation view of a sixth embodiment of the present wide aperture beam delivery system, adapted to raster scan a therapeutic ultrasound beam.
  • Fig. 25 is a top plan view of the raster scan generated by the system of Fig.
  • Fig. 26 is a sectional side elevation view of a sixth embodiment of the present wide aperture beam delivery system, comprising a depth adjusted transducer and a rotating ultrasonic mirror.
  • Fig. 27 is a sectional side elevation view of a seventh embodiment of the present wide aperture beam delivery system, comprising a plurality of individual transducers.
  • Fig. 28 depicts a simplified block diagram of an electronic system to drive the transducer of Fig. 27. 3990
  • Fig. 29 is a front view of a eighth embodiment of the present wide aperture beam delivery system, comprising a two dimensional transducer array.
  • Fig. 30 graphically presents blood pressure ratio data for rabbit ischemic hind limb experiments.
  • Fig. 31 graphically presents blood flow data for rabbit ischemic hind limb experiments.
  • Fig. 32 graphically presents angiographic score data for rabbit ischemic hind limb experiments.
  • the present invention provides a variety of wide beam ultrasound delivery systems which have the advantage of being able to deliver a uniform exposure of therapeutic ultrasound energy over a much larger volume of tissue than previous systems.
  • An advantage of such a wide beam delivery is that therapeutic ultrasound can be delivered across an entire target region into which a drug, DNA, or other therapeutic substance has been injected.
  • the present invention can be used to promote the cellular uptake of the drug, DNA, or other therapeutic substance prior to, concurrently with, immediately after, or substantially after its injection as the drug, DNA, or other therapeutic substance disperses through a region of a patient's musculature or organ.
  • a therapeutic injection of DNA into a human patient will typically diffuse into the patient's musculature.
  • ultrasonic imaging has demonstrated that an injection bolus typically follows muscle fibers and may spread across a length of five or more centimeters parallel to the muscle fiber and perhaps over a width of one to two centimeters normal to the muscle fibers.
  • a uniform dose of therapeutic ultrasound can be delivered to an extended section of vascular tissues at risk of intimal hyperplasia, such as coronary or peripheral arteries following vascular intervention or veins and arteries following graft insertion or the creation of a fistula. As such, the present invention can be used to minimize intimal hyperplasia.
  • bio-effects of the ultrasonic energy delivered by this invention are primarily mechanical in nature (cavitational, pressure, or high frequency vibration) with minimal thermal contribution (heat due to absorption of energy or energy conversion). As such, unwanted tissue heating is avoided.
  • MI P. [MPa] / sqrt ( F [MHz] )
  • the tolerated range for medical diagnostic equipment is up to an MI of 1.9. MI values above approximately unity represent acoustic levels which can cause mechanical bio- effects in human subjects.
  • a TI of 1 implies a temperature increase in normally vascularized muscle tissue of one Centigrade degree.
  • the FDA standard for a maximum temperature of surface contact ultrasound devices is 41 degrees C. "Deep heat" ultrasound therapy devices may generate higher temperatures within tissue. In the vascular arena, however, even slight temperature excursions may cause unwanted formation and accumulation of clot. Moreover, increased temperature of tissue may cause inflammation in the area of treatment. Therefore, TI values in excess of four are generally considered the threshold for causing undesirable bio-effects.
  • TI values greater than four may be calculated in accordance with the techniques described above.
  • the TI parameter as defined represents a steady state condition, not a short term "transient" exposure.
  • adequate doses of ultrasound can be delivered to achieve enhanced cellular absorption and/or transfection before thermal energy within the tissues generates an unacceptable temperature.
  • the AIUM definition of TI used herein refers to the continuous TI, as compared to the transient TI.
  • ultrasound energy is applied with a transient TI of less than 4, and more preferably less than 2, and most preferably less than 1.
  • Fig. 1 illustrates an exemplary aspect of the present invention, in which
  • Fig. 2 illustrates another exemplary aspect of the present invention, in which ultrasonic therapy alone is directed to the venous side 20 of an artero-venous (A-N) graft 22 in a patients arm.
  • An ultrasound transducer 24 with a wide field of view is placed either in the surgical incision 26 and coupled with sterile fluid such as saline or is placed over the skin post surgery (not shown). Equivalently (but not depicted), an ultrasonic transducer can be placed into a surgical incision for therapy after fistula creation or on the patient's skin for post surgical procedure vascular therapy.
  • the ultrasound field will be uniform across the two orthogonal directions of the sample tissue and through its depth.
  • Fig. 3 depicts the lateral profile 30 of a preferred ultrasonic beam 32 of the wide field transducer 16 superimposed over the region 14 of substance diffusion in the muscle 12 of a patient's leg 34.
  • the acoustic amplitude will be uniform within prescribed limits 36 over the region of interest 38. Outside of this region of interest, the acoustic amplitude may fall off in any manner.
  • Fig. 4 depicts the axial beam profile 40 for the same clinical configuration as in Fig. 3.
  • the acoustic amplitude will again be uniform within prescribed limits 42 through the depth 44 of tissue 14 containing the injected substance. Again, proximal or distal to the region of interest, the acoustic beam may take any other amplitude provided bio-effects remain within acceptable limits.
  • Preferred and exemplary prescribed limits 36 and 42 for the uniformity of the ultrasound beam field will be within plus/minus 5 dB across its width, or across the width of the target region if an ultrasonic beam is scanned across a target region, as will be described. More preferably, the uniformity will be within plus/minus 3 dB, and most preferably within plus/minus 1.5 dB.
  • the area of the target region in the human body will vary with the application.
  • the area of the ultrasound beam field will be at least 0.5 cm2, and more preferably, at least 1.0 cm2, and most preferably, at least 10 cm2.
  • Doppler systems are designed to electronically or mechanically scan a highly focused beam 50 of higher frequency (typically 2 to 30 MHz) ultrasound through a patient's body 52, with lateral beam widths in the range from typically one millimeter to one hundred microns. Short transmit bursts with on the order of one to three cycles provide best axial resolutions. Peak amplitudes are limited to that energy just sufficient to create images out to the point of degrading resolution. While these systems deliver an effectively uniform dose of ultrasound energy over the width of the scan plane 54, the scan planes 54 are typically narrow and one dimensional, frequencies are generally too high for a predominantly mechanical effect in tissue, peak amplitudes are insufficient for a biological effect, and duty cycle at any one location is far below that required for a biological effect.
  • higher frequency typically 2 to 30 MHz
  • Fig. 6A depicts the lateral beam profile 60 from a typical diagnostic ultrasound imaging system. These profiles are quite narrow down to typically 30 to 50 dB from peak amplitude and thence broaden substantially. Across the scan plane, mechanically swept systems typically maintain the same peak amplitude as a function of angle while the phased array systems might typically see a 6 to 12 dB variation in amplitude 62, as depicted in Fig. 6A. In the cross plan (orthogonal to the scan plane), the beam exhibits a very narrow profile 64 as depicted in Fig. 6B.
  • Fig. 7 depicts the axial profile 70, the signal strength down the central axis of the transducer. Near the focal zone, the beam achieves peak amplitude, which is relatively uniform over a moderate depth.
  • Transducers 80 for physical therapy as depicted in Fig. 8 are typically employed to develop deep heat in injured muscles 82. These devices are typically single element, unfocused transducers. Due to operation in the near field, these devices exhibit highly irregular ultrasonic intensities both as a function of depth and as a function of lateral position. Indeed, Fig. 9 depicts a modeled lateral profile 90 of a 16 millimeter diameter, 1 MHz, unfocused transducer at a distance of twenty millimeters from the surface. Across the aperture of the device, the variation of signal strength exceeds 15 dB. From the surface of the transducer to the focal distance, the shape of the lateral profile also varies radically with depth. Fig.
  • modeled axial profile 100 (ultrasonic intensity along the central axis of the transducer) for the same device.
  • High intensity focused ultrasound (HIFU) systems typically employ single element focused transducers which deliver beam profiles similar to those of diagnostic imaging systems. These transducers are thence swept over the surface of the patient to develop thermal lesions at the focal depth. The higher frequencies have minimal mechanical bio-effects.
  • the present invention exceeds the performance of the current existing ultrasound systems depicted in each of Figs. 6, 7, 8, 9, and 10, by instead exhibiting a uniform ultrasound field over a wide area as depicted in Figs. 3 and 4.
  • Fig. 11 is a sectional side elevation view of a first embodiment of the present wide beam uniform exposure ultrasound delivery system.
  • Ultrasound delivery system 110 comprises a housing 111 having a proximal end 112 and a distal end 114.
  • An ultrasound transducer 115 is disposed at the proximal end 112 of housing 111 as shown.
  • Housing 111 may preferably be generally cylindrical in shape and may be tapered to a narrow distal end 114, as shown.
  • Distal end 114 of housing 111 is preferably covered with a flexible skin-contact window 117 which may be supported against the skin of patient P.
  • a standard acoustic coupling gel is applied between window 117 and the skin of patient P, to facilitate the transmission of therapeutic ultrasound energy to the patient.
  • Housing 111 is preferably filled with an acoustically couplant material 113, which may preferably comprise a fluid such as water with or without additives or oil. Fluid 113 operates to conduct the beam of ultrasound energy therethrough from transducer 115 to skin-contact window 117.
  • acoustically couplant material 113 which may preferably comprise a fluid such as water with or without additives or oil. Fluid 113 operates to conduct the beam of ultrasound energy therethrough from transducer 115 to skin-contact window 117.
  • transducer 115 may preferably be flat and circular in shape, as shown.
  • the diameter of transducer 115 may be in the range of 10 mm to 100 mm, yielding a surface area of 0.8 cm to 80 cm .
  • Transducer 115 may be made of a piezoelectric ceramic material, for example, a PZT ceramic, or more specifically, a PZT-8 ceramic, or other variation of a hard piezoelectric ceramic optimized for high power operation.
  • PZT-8 ceramic materials or equivalents are available from most vendors of piezoelectric ceramic, such as Morgan Matroc, Inc., of Cleveland, OH.
  • the transducers might be fabricated from single crystal piezoelectrics, such as those manufactured by Stratum Technologies, Inc., of State College, PA.
  • the present piezoelectric materials are not limited, but may alternatively be made from families of materials including lithium niobates, lead titonates, lead metaniobates, various composites, and any other suitable materials.
  • variations on the transducer design may also include using magnetostrictive materials as the ultrasonic driver elements.
  • Transducer 115 is shown in Fig. 11 to be in direct contact with the fluid path medium 113. If it is necessary to electrically insulate the transducer from the fluid medium, the transducer may be coated with an insulating material, such as a Humiseal 1B31 acrylic manufactured by the Chase Corp. of Woodside, NY. Alternatively, the front surface of the transducer may feature one or more impedance matching layers, for purposes of wave form shaping, mechanical strength, or again, electrical insulation. In the case of a single impedance matching layer, a quarter wave length thickness of a 3103 casting epoxy manufactured by Tra-Con of Bedford, MA is desirable. Ideally, the impedance matching layers will present with minimal acoustic attenuation, as any absorbed energy will heat the delivery device.
  • an insulating material such as a Humiseal 1B31 acrylic manufactured by the Chase Corp. of Woodside, NY.
  • the front surface of the transducer may feature one or more impedance matching layers, for purposes of wave form shaping, mechanical strength, or again
  • An air pocket 118 may be provided on the back side of transducer 115 such that substantially all of the ultrasound energy emitted by transducer 115 is then directed distally through fluid 113 toward skin-contact window 117 at distal end 114 of housing 111.
  • the air-ceramic interface on the back side of the transducer provides an excellent reflector of acoustic energy back to the distal direction. Air is furthermore an extremely poor conductor of ultrasound energy.
  • a low impedance acoustic material with a low acoustic attenuation may be utilized for purposes of mechanical strength in the device.
  • the structural side walls 111 of the delivery device housing are ideally coated with anti reflective, highly absorptive material, such as heavily loaded silicone rubbers.
  • Figs. 12A and 12B illustrate modeled lateral beam profiles 120 and 122 for the system of Fig. 11, featuring a 1 MHz unfocused transducer 25.4 mm in diameter.
  • the beam profiles correspond to the ultrasound amplitudes perpendicular to axis A2 at depths of 107 mm and 200 mm from skin-contact window 117, which correspond to the center of focal region and the transducer far field.
  • Fig. 13 illustrates a modeled axial beam profile 130 for the same transducer.
  • the ultrasonic axial amplitude 130 is uniform to within 6 dB from approximately 62 mm off the transducer surface to approximately 300 mm off the surface.
  • the lateral profile 120 suggests uniformity to within 6 dB over a diameter of 10 mm.
  • the lateral profile 122 suggests uniformity to within 6 dB over a diameter of 17 mm.
  • the length of transducer housing 111 and consequently the length of the water path 113 can be adjusted to position either the focal zone or any far field point onto the middle of the muscle injection point, such adjustment providing a corresponding ultrasonic beam width. It is seem that the lateral beam profiles 120 and 122 of Figs.
  • the present uniform wide field of ultrasound energy will vary by less than 10 dB (and more preferably 6 dB and most preferably 3 dB) across an axial distance from the skin contact window to a distance beyond the depth of the target region of interest.
  • the present uniform wide field of ultrasound energy will vary by less than 10 dB (and more preferably 6 dB and most preferably 3 dB) across a beam width of at least 8mm, more preferably 12mm, and most preferably 35mm.
  • Fig. 14 depicts a simplified block diagram of an electronic system 140 to drive the transducer of Fig. 11.
  • the user operates the system through a user interface 141 to a computer or controller subsystem 142.
  • the computer controls a signal generator 144 to generate the RF driving signal, a modulator 145 to format the number of cycles per burst and to set the burst rate, a variable gain power amplifier 146, an impedance matching circuit 147, and finally the transducer 148.
  • the transducer may be coupled to the patient via a solid acoustic medium, or buffer rod, as compared to the fluid medium discussed above.
  • the solid acoustic medium would thence be decoupled acoustically from the delivery device housing.
  • the solid medium would comprise a material with an acoustic impedance between that of the transducer piezoelectric ceramic (typically 33 Mrayls) and that of the patient (typically 1.5 Mrayls), and further would ideally have a minimum acoustic attenuation (ideally on the order of 0.1 dB/MHz/cm or less), as such attenuation would result in attenuation of the ultrasonic beam and consequent device heating.
  • the solid medium include aluminum metal and glass.
  • these solid medium materials might feature acoustic impedance matching layers, in the form of quarter wave length thickness of intermediate acoustic impedance materials generally from the families of polymers or loaded epoxies. Acoustic impedance matching methods are known to persons skilled in the art.
  • Fig. 15 depicts an alternate embodiment 150 of the present wide aperture ultrasound beam delivery system in which a curved ultrasound transducer 155 is suspended within housing 151. Being curved, transducer 155 narrows the width of beam B of ultrasound energy which passes through fluid 153 and through skin-contact window 157, and which then broadens within the patient P. Similar to the above described system, an air pocket 158 is provided to ensure that maximal ultrasound energy emitted from transducer 155 passes towards and into patient P. As seen in Fig. 15, beam B of ultrasound energy is narrowed through a focal region 159 which is disposed within fluid 153 such that a wide uniform field of ultrasound energy spreads across a rather large target region T in patient P into which DNA or other therapeutic biological substance has been injected. In this manner, the distance from the transducer 155 to target region T can be reduced for a smaller physical size of the delivery device.
  • Fig. 16 shows yet another embodiment of the present invention in which an acoustically refractive material 166 is mounted to ultrasound transducer 165 to shape the acoustic beam B to a focal region 169 at an appropriate depth in patient P.
  • acoustically refractive material 166 may comprise silicon rubber
  • skin-contact window 167 may have a curved shape to assist in further narrowing or widening beam B of ultrasound energy passing therethrough.
  • the single element beam profiles depicted in Figs. 12A and 12B can be substantially broadened by the addition of an annulus 172 around a central disc 170, as depicted in Fig. 17.
  • the outer diameter of the annulus is equal to the square root of two times the outer diameter of the central disc.
  • the gap between the central disc and the annulus shall be sufficient to prevent acoustic cross talk between the two pieces of piezoelectric ceramic.
  • Fig. 18 depicts a simplified block diagram of an electronic system 180 to drive the transducer of Fig. 17.
  • the user operates the system through a user interface 181 to a computer or controller subsystem 182.
  • the computer controls a signal generator 184 to generate the RF driving signal, a modulator 185 to format the number of cycles per burst and to set the burst rate, a time delay or phase shifting circuit 189, variable gain power amplifiers 186A and 186B, impedance matching circuits 187 A and 187B, and finally the transducers 188 A and 188B.
  • the amplifiers 186A and 186B need not be operated at the same gain setting.
  • the phase shifting circuit can be set for any angle from zero to 360 degrees.
  • Fig. 19 depicts a modeled lateral beam profile 190.
  • the 6 dB beam width has now been opened up to 25.5 mm, albeit at an approximately 10 dB loss of signal strength.
  • Fig. 20 depicts the modeled axial profile 200 for this central disc and annulus pair, showing the 10 dB depression in the focal zone, when compared with the modeled axial profile of Fig. 13.
  • Figs. 21 A and 2 IB depict modeled lateral beam profiles at 10 mm proximal and 10 mm distal with respect to the lateral profile of Fig. 19, showing retention of a wide beam over depths of field relevant to the current applications.
  • Figs. 21 A and 2 IB show profiles with 6 dB beam widths of 24.3 mm and 26.8 mm, respectively.
  • the present invention is not limited to one annulus around a central disc, with the specific amplitudes and phases of the driving signals as stated above. Indeed, in the extreme, an infinite set of annuli with an infinite aperture can be programmed to generate a perfectly square beam profile with no ripple across the beam. With regard to driving electronics, additional channels comprising a phase shifter or time delay, power amplifier, and impedance matching circuit will be required.
  • Fig. 22 shows yet another embodiment of the present invention in which a cylindrical-shaped ultrasound transducer 225 is suspended within housing 221.
  • transducer 225 preferably has a hollow, air-filled interior 228 such that ultrasound energy emitted by transducer 225 is directed radially outwards through fluid 223 towards curved acoustic reflector 229, which in turn reflects and directs the beam of ultrasound energy passing through skin-contact window 227, and into patient P.
  • An advantage of this invention is that it provides a compact housing for shaping a therapeutic ultrasound beam at a preferred depth within a patient. This design also provides a greater surface area of the piezoelectric ceramic for greater ultrasonic energy delivery.
  • Fig. 23 shows yet another embodiment of the present invention in which an annular-shaped ultrasound transducer 235 is disposed near distal end 234 of housing 231.
  • Transducer 235 directs ultrasound energy through fluid 233 towards acoustic reflector 239, which in turn directs the ultrasound energy through fluid 233 and through skin-contact window 237, passing into patient P.
  • both transducer 235 and acoustic reflector 239 can be curved, either convexly or concavely, to assist in focussing or defocusing the beam of ultrasound energy to a target region T in the patient.
  • An advantage of this embodiment of the invention is that a large ratio of transducer cross sectional area to beam cross sectional area can be achieved, offering a greater margin on the drive capabilities, thus allowing the piezoelectric ceramic to be driven at comparatively lower voltages.
  • An annular air pocket 238 is provided behind transducer 235 such that substantially all of the ultrasound energy emitted from transducer 235 is directed towards acoustic reflector 239.
  • delivery device 240 comprises a housing 241 in which ultrasound transducer 245 is mounted on preferentially orthogonal axes to rotate back and forth about pivot points 242 (only one pivot point shown for ease of illustration). As such, transducer 245 is adapted to rotate about pivot point 242 in two perpendicular axes such that a narrowed beam 249 of therapeutic ultrasound energy can be raster-scanned across target region T.
  • FIG. 25 A typical top plan view of a raster scan 251 generated by the system of Fig. 24 is shown in Fig. 25 in which a narrow diameter focal region 259 is raster scanned across a larger diameter target region T. If it is desired to achieve a specific duty cycle of ultrasonic emission at any point in the target region, the physical distance of continuous emission of the raster scan transducer may be adjusted. A specific percentage duty cycle requires that the effective beam width of the transducer be over the specific point in the sample for the same percentage of time (continuous or a higher burst rate emission from the transducer is now required).
  • any of the transducers as depicted in Figs. 11, 15, 16, 17, 22, and 23 may be mounted in the pivot points 242 of the delivery device 240 of Fig. 24. All of the individual features may be collected in whole or in part in the assembly of the delivery device.
  • Fig. 26 depicts yet another scanning ultrasound delivery device 320 in which the transducer 325 with its air backing cavity is mounted with the ultrasonic beam B parallel to the surface of the patient.
  • the ultrasonic beam B passed though the fluid medium 323, reflects of an acoustic mirror 321 with air backing 328, and proceeds though patient coupling window 327 into the patient P.
  • the provision of an air backing behind the mirror eliminates any possibility of refractive ultrasonic energy entering the mirror and reradiating in destructive interference with the primary ultrasonic beam.
  • the reflective surface may be planar or curved for narrowing or widening the ultrasonic beam B.
  • the transducer By mounting the transducer on longitudinal shaft 322, the transducer may be pushed forward or pulled backward so as to cause the focal point or the point of optimal ultrasonic beam to be placed deeper of shallower in the patient.
  • the mirror rotational shaft 324 By mounting the mirror rotational shaft 324, the mirror can be rotated or toggled, thus sweeping the ultrasonic beam B across a section of the patient.
  • Fig. 27 depicts yet a further scanning ultrasound delivery device 260, comprising a multitude of single element or annular array transducers 265 of the type as described above, with or without na ⁇ owing or widening means, for the purpose of illuminating a yet larger area.
  • the transducers might be mounted in a single file or may be arranged in parallel rows (not shown for ease of illustration).
  • the delivery device housing 261 will contain fluid 263 for the propagation of ultrasonic energy from transducers 265 to the device housing window 267 and into the patient P. If the transducers 265 are larger in lateral dimensions than their acoustic beams in the target region T of the patient, then the transducers can be mounted in a tilted manner as shown.
  • the signal generator system 270 as sketched in Fig. 28 comprises a central controller 272 with drives a frequency generator 274, a modulator 275, a switch (multiplexer) 279, and amplifiers 276 and impedance matching circuits 277 for each transducer 278 in the array.
  • the controller sequentially switches the signal from the output of the modulator or preamplifier stage to the final amplifier stage of the respective transducer channels, thus driving all transducers sequentially during one pulse repetition period.
  • individual transducers 265 may be operated such that their activation is staggered, with each transducer, or combinations of transducers, being turned on and off in sequence.
  • An advantage of separately controlling the operation of each of transducers 265 individually is that system duty cycle can be increased.
  • Fig. 29 shows a two dimensional ultrasound transducer array 280, comprising a plurality of individual ultrasound transducer elements 281, 282, 283, etc.
  • each of ultrasound elements 281, 282, 283, etc. are preferably individually controlled with a dedicated time delay and power amplifier such that the phases of the signals of each of elements 281, 282, 283, etc., could be adjusted to direct a shaped composite ultrasound beam to a specific location within the patient's body, or alternatively, to sweep the beam with a specified beam width in a raster scan.
  • Each of the elements 281 , 282, 283, etc. must be of sufficiently small size such that their beam widths cover the total region of interest.
  • the transducer array of Fig. 29 may be mounted within a fluid filled housing as described herein, or may alternatively be applied directly to the patient's skin.
  • Each thigh had 9 samples collected in a 3 by 3 array in the area exposed to ultrasound.
  • the muscle samples had dimensions of about 1 x 1 x 0.5 cm (WxLxH) .
  • Protein was then extracted from the tissue and measured for beta-galactosidase enzyme activity and total protein. Beta- galactosidase activity was normalized to the protein content and expressed as activity per protein mass. For each rabbit thigh, an average beta-galactosidase activity was then calculated from the 9 samples.
  • ischemia was created in the rabbit hind limb by the complete removal of the internal femoral artery ten days before treatment.
  • the rabbits were evaluated 30 days post treatment in three areas: blood pressure ratio - the ratio of blood pressure in the ankle of the ischemic hind limb compared to that in untouched animals; blood flow - the flow rate measured at the distal end of the iliac artery with a Doppler flow wire; and angiographic score - the number of native arteries, collateral arteries, and capillaries visible in each square of a grid on an angiographic image.
  • NEGF expressing plasmid D ⁇ A 100 micro grams was injected into the hind limbs of young rabbits.
  • 500 micro grams of NEGF expressing plasmid D ⁇ A was injected into the hind limbs of old rabbits. Old rabbits were specifically selected for the second experiment because they are angiogenetically impaired.
  • the use of a higher dose of NEGF expressing plasmid D ⁇ A in these animals would allow the demonstration of an ultrasonic enhancement in a normally plateaued, or saturated, biological system.
  • NEGF expressing plasmid D ⁇ A was injected into five sites on the thigh muscle followed immediately by ultrasound exposure of seven sites in close proximity to the injection sites.
  • Ultrasound in the range of 1 MHz, 1.8 MI and 6% duty cycle was applied with the wide beam delivery system illustrated in Fig. 11.
  • Comparisons were made to a rabbit control group and between rabbit groups to which ultrasound was, and was not, applied immediately following the NEGF expressing D ⁇ A injection.
  • Fig. 29 depicts the experimental blood pressure ratio results, where the blood pressure ratio is derived from blood pressure measurements at the ankle of the ischemic hind limb and the contra-lateral normal hind limb.
  • the proliferation of vascular smooth muscle cells in the neointimal layer of the artery can be reduced by at least 2% (in comparison with untreated controls) after seven days, often at least 4%, and sometimes 6% or greater.
  • the resulting reduction in hype ⁇ lasia mass after 28 days will typically be at least 10%, usually at least 20%, and preferably at least 30%. Such inhibitions can be achieved without significant necrosis of the smooth muscle cells. Broad, preferred, and exemplary values for each of these perimeters are set forth in table 3.
  • MI Mechanical Index
  • Duty Cycle (%) 0.1 to 100 0.2 to 10 0.2 to 2
  • transcutaneous ultrasonic energy in the form of the device of Fig. 11 was applied in the surgical incision on sheep during the creation of a fistula between the femoral arteries and veins and the implantation of a graft between the carotid artery and the jugular vein.
  • Each surgical site had three ultrasound exposures, the first directly on the center of the site, followed by proximal and distal exposures.
  • Each ultrasound exposure featured a beam width of approximately 10 mm, for 120 seconds, at an MI level of approximately 3.0, with a duty cycle of one percent (30 cycles at 315 Hz repetition rate) and for a calculated increase in tissue temperature of less than 3 degrees Centigrade.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne un dispositif d'administration d'ultrasons à faisceau large permettant d'obtenir un champ d'exposition uniforme, utilisé pour améliorer l'absorption de substances injectées et/ou pour améliorer la transfection d'ADN dans les tissus d'un sujet humain ou réduire la quantité d'hyperplasie endoveineuse vasculaire chez des sujets humains à la suite d'une lésion vasculaire.
EP00914604A 1999-02-22 2000-02-16 Methodes et appareil destines a la therapie transcutanee par champs uniforme d'ultrasons Withdrawn EP1158909A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US364616 1989-06-09
US25529099A 1999-02-22 1999-02-22
US255290 1999-02-22
US36461699A 1999-07-29 1999-07-29
PCT/US2000/003990 WO2000048518A1 (fr) 1999-02-22 2000-02-16 Methodes et appareil destines a la therapie transcutanee par champs uniforme d'ultrasons

Publications (2)

Publication Number Publication Date
EP1158909A1 true EP1158909A1 (fr) 2001-12-05
EP1158909A4 EP1158909A4 (fr) 2003-02-05

Family

ID=26944596

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00914604A Withdrawn EP1158909A4 (fr) 1999-02-22 2000-02-16 Methodes et appareil destines a la therapie transcutanee par champs uniforme d'ultrasons

Country Status (6)

Country Link
EP (1) EP1158909A4 (fr)
JP (1) JP2002537013A (fr)
AU (1) AU3597100A (fr)
BR (1) BR0008397A (fr)
CA (1) CA2361150A1 (fr)
WO (1) WO2000048518A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837720B2 (en) 2000-06-20 2010-11-23 Boston Scientific Corporation Apparatus for treatment of tissue adjacent a bodily conduit with a gene or drug-coated compression balloon
US7135029B2 (en) 2001-06-29 2006-11-14 Makin Inder Raj S Ultrasonic surgical instrument for intracorporeal sonodynamic therapy
MXPA04007897A (es) 2002-02-15 2004-11-26 Celsion Corp Metodo y aparato para tratar el tejido adyacente a un conducto corporal con termocompresion y farmacos.
HU224572B1 (hu) 2002-11-05 2005-11-28 Khaled Awad Saleh Nashwan Készülék érrendszeri megbetegedésben szenvedők infra-, hallható- és ultrahang hullámok kombinációjával való kezelésére
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
JP5932195B2 (ja) * 2004-10-06 2016-06-08 ガイデッド セラピー システムズ， エル．エル．シー． ヒト表面組織の制御された熱処理のためのシステム
US8690778B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Energy-based tissue tightening
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US20150174388A1 (en) 2007-05-07 2015-06-25 Guided Therapy Systems, Llc Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue
US12102473B2 (en) 2008-06-06 2024-10-01 Ulthera, Inc. Systems for ultrasound treatment
HUE027536T2 (en) 2008-06-06 2016-10-28 Ulthera Inc Cosmetic treatment and imaging system
WO2010075547A2 (fr) 2008-12-24 2010-07-01 Guided Therapy Systems, Llc Procédés et systèmes pour réduire les graisses et/ou traiter la cellulite
US8911453B2 (en) * 2010-12-21 2014-12-16 Restoration Robotics, Inc. Methods and systems for directing movement of a tool in hair transplantation procedures
JP2012200454A (ja) * 2011-03-25 2012-10-22 Hitachi Medical Corp 薬剤導入装置及び薬剤導入システム
CN113648552A (zh) 2013-03-08 2021-11-16 奥赛拉公司 用于多焦点超声治疗的装置和方法
CN106470735B (zh) 2014-04-18 2019-09-20 奥赛拉公司 带式换能器超声治疗
EP3265167A1 (fr) * 2015-03-03 2018-01-10 Guided Therapy Systems, L.L.C. Procédés et systèmes de transport de matériaux à travers une membrane imperméable ou semi-perméable par l'intermédiaire de microcanaux créés artificiellement
WO2016147297A1 (fr) * 2015-03-16 2016-09-22 株式会社日立製作所 Dispositif d'administration de solution médicamenteuse et son procédé de fonctionnement
AU2017208980B2 (en) 2016-01-18 2022-03-31 Ulthera, Inc. Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof
SG11201809850QA (en) 2016-08-16 2018-12-28 Ulthera Inc Systems and methods for cosmetic ultrasound treatment of skin
KR102548194B1 (ko) 2016-12-22 2023-06-27 서니브룩 리서치 인스티튜트 경두개 초음파 치료 및 영상화 절차 수행을 위한 시스템 및 방법
TWI797235B (zh) 2018-01-26 2023-04-01 美商奧賽拉公司 用於多個維度中的同時多聚焦超音治療的系統和方法
US11944849B2 (en) 2018-02-20 2024-04-02 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound
US20220023607A1 (en) * 2020-07-21 2022-01-27 Sanuwave Inc. Pressure Waves for Vaccines, Genetic Modification and Medical Treatments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017018A1 (fr) * 1995-11-09 1997-05-15 Brigham & Women's Hospital Groupement aperiodique d'elements a ultra-sons commandes en phase
WO1997040679A1 (fr) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Procedes d'apport de composes dans une cellule
WO1998000194A2 (fr) * 1996-06-28 1998-01-08 Sontra Medical, L.P. Amelioration du transport transdermique par ultrason
WO1999039763A1 (fr) * 1998-02-10 1999-08-12 Children's Medical Center Corporation Administration de medicaments par ultrasons
WO2000006032A1 (fr) * 1998-07-29 2000-02-10 Pharmasonics, Inc. Ameliorations par ultra-sons de l'injection de medicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5197946A (en) * 1990-06-27 1993-03-30 Shunro Tachibana Injection instrument with ultrasonic oscillating element
US5667487A (en) * 1993-04-07 1997-09-16 Henley; Julian L. Ionosonic drug delivery apparatus
US5490840A (en) * 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
US5752515A (en) * 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017018A1 (fr) * 1995-11-09 1997-05-15 Brigham & Women's Hospital Groupement aperiodique d'elements a ultra-sons commandes en phase
WO1997040679A1 (fr) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Procedes d'apport de composes dans une cellule
WO1998000194A2 (fr) * 1996-06-28 1998-01-08 Sontra Medical, L.P. Amelioration du transport transdermique par ultrason
WO1999039763A1 (fr) * 1998-02-10 1999-08-12 Children's Medical Center Corporation Administration de medicaments par ultrasons
WO2000006032A1 (fr) * 1998-07-29 2000-02-10 Pharmasonics, Inc. Ameliorations par ultra-sons de l'injection de medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No Search *
See also references of WO0048518A1 *

Also Published As

Publication number Publication date
EP1158909A4 (fr) 2003-02-05
AU3597100A (en) 2000-09-04
BR0008397A (pt) 2002-02-05
WO2000048518A1 (fr) 2000-08-24
JP2002537013A (ja) 2002-11-05
WO2000048518A9 (fr) 2001-09-27
CA2361150A1 (fr) 2000-08-24

Similar Documents

Publication Publication Date Title
US6575956B1 (en) Methods and apparatus for uniform transcutaneous therapeutic ultrasound
US20030229331A1 (en) Methods and apparatus for uniform transcutaneous therapeutic ultrasound
EP1158909A1 (fr) Methodes et appareil destines a la therapie transcutanee par champs uniforme d'ultrasons
Rao et al. Sonophoresis: recent advancements and future trends
AU754022B2 (en) Ultrasonic enhancement of drug injection
US7530958B2 (en) Method and system for combined ultrasound treatment
US20020068869A1 (en) Drug delivery catheter with internal ultrasound receiver
US6464680B1 (en) Ultrasonic enhancement of drug injection
EP1711109B1 (fr) Production localisee de microbulles et regulation des effets de chauffe et de cavitation au moyen d'ultrason ameliore
US9011336B2 (en) Method and system for combined energy therapy profile
US7591996B2 (en) Ultrasound target vessel occlusion using microbubbles
US7135029B2 (en) Ultrasonic surgical instrument for intracorporeal sonodynamic therapy
US6484052B1 (en) Optically generated ultrasound for enhanced drug delivery
US12064389B2 (en) Method for improving kidney function with extracorporeal shockwaves
US20030009153A1 (en) Ultrasonic enhancement of drug injection
US20060036195A1 (en) Pressure pulse/shock wave therapy methods for organs
EP3096838A1 (fr) Procédés et systèmes de contrôle de dépôt d'énergie acoustique dans divers média
US20060241522A1 (en) Ultrasound devices and methods for treating ischemia and other cardiovascular disorders
US20090171248A1 (en) Ultrasound treatment of adipose tissue with fluid injection
Bhardwaj et al. Phonophoresis in Physiotherapy: Mechanisms, Applications, and Emerging Trends for Enhanced Drug Delivery and Therapeutic Efficacy
Izadifar et al. Applications and safety of therapeutic ultrasound: current trends and future potential
CA2710675A1 (fr) Traitement ultrasonore de tissu adipeux presentant une caracteristique de vide
WO2009098607A2 (fr) Traitement par ultrasons de tissu adipeux avec injection de fluide
WO2023234231A1 (fr) Dispositif de traitement par ultrasons pour maladie cardiaque
US20210393476A1 (en) Improved acoustic shock wave therapeutic methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010925;LT PAYMENT 20010925;LV PAYMENT 20010925;MK PAYMENT 20010925;RO PAYMENT 20010925;SI PAYMENT 20010925

R17P Request for examination filed (corrected)

Effective date: 20010924

A4 Supplementary search report drawn up and despatched

Effective date: 20021219

17Q First examination report despatched

Effective date: 20030630

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041027